NEWS | January 3, 2023

Competition Introduces MedTech Startup to Global Venture Capital Audience

CINCINNATI, OH – January 3, 2023 – Cincinnati-based Sense Neuro Diagnostics is pursuing new international  investment opportunities after coming in second place in the Unicorn CUP Finals startup competition. The pitch  event is affiliated with Unicorn Events, the world’s largest startup pitch competition that focuses on discovering  extraordinary startups that have the potential to achieve a valuation of $1 billion or more. 

A panel of eight judges representing funds from around the globe judged the 4th quarter Unicorn CUP Finals, in  which eight startups faced off after previously winning their respective industry-specific pitch battles. Indonesian  clean energy startup EX Zero Carbon Inc. placed first. Sense Neuro Diagnostics, Rhoman Aerospace in Los Angeles, and AdviNOW Medical in Scottsdale, Arizona, all tied for second place. 

Sense Neuro Diagnostics is developing innovative, non-invasive technology that can collect 360 data points in 2.5  seconds to detect brain hemorrhage or stroke type. This technology has the potential to help first responders,  emergency department personnel, neuro ICU teams, and military field hospitals assess and monitor traumatic brain  injuries and assess for different stroke types. 

“The Unicorn CUP is a tremendous opportunity for Sense to grow awareness on an international stage and connect  to investors and mentors who will help us bring this life-saving technology to market,” says Geoff Klass, president &  CEO, Sense Neuro Diagnostics. “ 

At the pitch event, Sense Neuro Diagnostics had the opportunity to present its novel technology to renowned  international VCs, business angels, and corporations searching for new startups to fund.  

This honor follows preliminary wins for Sense Neuro Diagnostics at Unicorn Pitch Arizona in the HealthTech and  BioTech category in June, and at the Unicorn Battle for North America in the HealthTech & BioTech category in  September. 

Sense Neuro Diagnostics’ in-hospital device is currently undergoing clinical trials at more than 20 sites across the  United States, Canada, and India. An additional five sites are evaluating its military field device.